Pemvidutide
vs Retatrutide.
Compare pemvidutide and retatrutide by dual versus triple agonism, obesity and MASH evidence, Phase 2 and Phase 3 results, safety, and FDA status.
What is the difference?
Pemvidutide and retatrutide are different investigational once-weekly peptides with no head-to-head trial. Pemvidutide activates GLP-1 and glucagon receptors in a balanced dual-agonist design and is currently focused on MASH and alcohol-related liver conditions after a completed Phase 2 obesity study. Retatrutide activates GIP, GLP-1, and glucagon receptors and has reported Phase 3 obesity results. Neither is FDA approved. Retatrutide's larger and longer Phase 3 headline cannot establish that it is better for MASH, liver outcomes, safety, or an individual, while pemvidutide's FDA designations do not establish approval or comparative superiority.
See the useful differences first.
Start with identity, current US status, trial coverage, and the evidence relationship. Then carry the exact pair into a country-aware workspace without losing either record.
Pemvidutide
Investigational - not FDA approved
- Route
- Once-weekly subcutaneous injection
- Registry
- 9 matched NCT records
- Sponsor
- Altimmune
Retatrutide
Investigational - not FDA approved
- Route
- Once-weekly subcutaneous injection
- Registry
- 34 matched NCT records
- Sponsor
- Eli Lilly and Company
Pemvidutide vs Retatrutide: how direct is the evidence?
No participant in the cited sources was randomized between Pemvidutide and Retatrutide. Identity, mechanism, route, trial design, and regulatory status can be compared. Subtracting percentages from separate studies would create a treatment effect the evidence did not test.
Pemvidutide
Balanced 1:1 GLP-1 and glucagon receptor dual agonist
- Route
- Once-weekly subcutaneous injection
- Stage
- Phase 2 programs active; MASH Phase 3 planned
- Status
- Investigational - not FDA approved
Two evidence records, no shared randomization.
Treat percentages as separate source records. Do not subtract them, divide them into weekly rates, or use the larger value to name a winner.
No randomized head-to-head trialRetatrutide
GIP + GLP-1 + glucagon receptor agonist
- Route
- Once-weekly subcutaneous injection
- Stage
- Phase 3 program reporting results
- Status
- Investigational - not FDA approved
The current exact-intervention dataset contains 268 unique NCT records across 13 tracked investigational programs. Counts describe registry coverage, not comparative evidence strength.
matched NCT records
- Recruiting
- 1
- Results posted
- 0
- Recruiting site observations
- 8
matched NCT records
- Recruiting
- 2
- Results posted
- 2
- Recruiting site observations
- 450
Compare the named molecules, active components, sponsors, and receptor strategies.
Compare the studied route, frequency, development phase, and exact program record.
Compare exact approvals, applications, and investigational status in the jurisdiction being checked.
Treat percentages as separate source records. Do not subtract them, divide them into weekly rates, or use the larger value to name a winner.
Use only adverse-event evidence reported for the cited protocol. Separate studies cannot establish which program is safer.
No group result, receptor count, route, approval milestone, or chart position predicts the best choice for one person.
Check both programs in the same market.
Approval, trial activity, product registration, pharmacy rules, and seller authority are country specific. Open both records before treating a status from one market as valid in another.
Pemvidutide
Balanced 1:1 GLP-1 and glucagon receptor dual agonist
- Route
- Once-weekly subcutaneous injection
- Stage
- Phase 2 programs active; MASH Phase 3 planned
- Status
- Investigational - not FDA approved
- Featured trial anchors
- NCT05989711 · NCT06987513 · NCT07009860 · NCT05006885
Retatrutide
GIP + GLP-1 + glucagon receptor agonist
- Route
- Once-weekly subcutaneous injection
- Stage
- Phase 3 program reporting results
- Status
- Investigational - not FDA approved
- Featured trial anchors
- NCT05929066 · NCT05931367 · NCT05882045
Compare the field, then read the limit.
The pair attracts interest because both include glucagon activity and because their largest weight-loss percentages are often listed without trial context. The current evidence can compare receptor design, sponsor priorities, development stage, MASH evidence, obesity duration, estimands, and adverse-event reporting. It cannot compare efficacy directly because MOMENTUM and TRIUMPH-1 were conducted in different phases, populations, dose plans, durations, and analytical frameworks.
| Field | Pemvidutide | Retatrutide | How to interpret it |
|---|---|---|---|
| Receptor strategy | Balanced GLP-1 and glucagon receptor dual agonist | GIP, GLP-1, and glucagon receptor triple agonist | Retatrutide adds GIP activity, but target count alone cannot predict comparative clinical value or tolerability. |
| Obesity evidence anchor | 15.6% mean change at 48 weeks in Phase 2 MOMENTUM | 28.3% efficacy-estimand mean change at 80 weeks in Phase 3 TRIUMPH-1 | Different phases, durations, populations, doses, and estimands make a direct percentage ranking invalid. |
| Liver evidence | Completed MASH Phase 2b with planned MASH Phase 3 development | Metabolic and obesity development includes additional disease studies but not the same MASH protocol | A dedicated MASH program answers disease-specific questions that cannot be inferred from an obesity weight endpoint. |
| Regulatory milestone | Breakthrough Therapy for MASH and Fast Track for MASH and alcohol use disorder | Phase 3 program active and reporting | Designations and topline results are development milestones, not FDA approval, a final label, or commercial availability. |
| Current access status | Investigational and not FDA approved | Investigational and not FDA approved | Neither program name identifies an approved retail product or authenticates an online research listing or supplier. |
Why the headline numbers do not name a winner.
MOMENTUM reported 15.6% mean weight loss with weekly pemvidutide 2.4 mg at week 48 versus 2.2% with placebo in a 391-person Phase 2 study. TRIUMPH-1 reported 28.3% mean loss with retatrutide 12 mg at week 80 under an efficacy estimand and 25.0% under a treatment-regimen estimand in Phase 3. The numbers are not matching statistical measures. Dividing by time or subtracting them ignores dose escalation, population, placebo response, study phase, adherence, rescue treatment, discontinuation, and missing-data assumptions.
Keep the comparison honest.
- 01
Keep MOMENTUM, IMPACT, and TRIUMPH records separate and attach every result to its population, disease question, dose, duration, and estimand.
- 02
Do not convert 48-week and 80-week percentages into linear rates or use receptor count as a substitute for randomized comparative evidence.
- 03
Treat FDA designations, Phase 3 reporting, and online product names as distinct facts that do not establish approval, supply, or authenticity.
A country-specific approval, clinical trial, or matching name does not authenticate an online product or establish access elsewhere. This page contains no treatment recommendation, buying route, personal-use protocol, or affiliate link.
Open the safety and status guide →